Yang Tang is counsel in the firm’s Intellectual Property practice. She provides clients with a broad range of services, including patent procurement, patent strategy counseling, patent portfolio evaluation, due diligence, patentability assessment, validity assessment, non-infringement opinion, freedom to operate analysis, and appeals and oral hearings before the U.S. Patent Trial and Appeal Board. She has managed worldwide patent portfolios for large pharmaceutical clients. She also has extensive experience coordinating with various foreign law firms and assisting in opposition proceedings in foreign jurisdictions. In addition, she has experience in supporting depositions and other litigation proceedings as well as post-grant proceedings, such as inter partes review (IPR).
Yang has represented clients in biotechnology, life sciences, pharmaceutical technology, chemistry, and medical device industries. Her technical areas include drug discovery, drug development, drug formulation, nanotechnology, in vivo and in vitro diagnostics, antibody therapeutics, nucleic acid therapeutics, vaccine development, immunology, recombinant DNA and protein expression, genetically engineered microorganisms, genetic screening and biomarkers, and food and dairy products. Representative clients include startup companies, private and public research institutions and universities, biotech companies, and large pharmaceutical companies.
Prior to her law practice, Yang was trained as a molecular biologist and worked in the biotech industry as a research scientist for over seven years. She has technical experience in drug discovery, antibiotics development, high throughput compound screening, DNA mutagenesis, bacteria mutagenesis, recombinant DNA and protein expression and purification, DNA sequence search and alignment, cell culture, gene knock-out and genetically engineered animals and development of humanized antibodies.